A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Metastatic Sarcoma Clinical Trial

— IND200  

Official title:

A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01112384
• Other study ID #: I200
• Status: Completed
• Phase: Phase 2
• Start date: October 21, 2010
• Est. completion date: January 16, 2014

Study information

• Verified date: April 2020
• Source: Canadian Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out what effects a new drug SB939 has on you and your sarcoma.

This research is being done because there is a need for better treatment options for advanced or recurring sarcoma.

SB939 has been shown to shrink tumours in animals and some people and seems promising but it is not clear if it has any positive effects in sarcoma.

Description:

Objectives:

1. - To determine the efficacy of SB939 in translocation associated sarcoma patients.

2. - To determine response duration, stable disease rate and progression free survival.

3. - To evaluate toxicity of SB939.

4. - To investigate potential molecular factors predictive of response.

60mg SB939 will be given every other day 3 times a week for 3 weeks followed by a week off. Patients may receive a maximum of 12 cycles if they have a response to treatment in the absence of disease progression or unacceptable toxicity. Patients with stable disease may continue therapy for a maximum of 6 cycles.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 16, 2014
• Est. primary completion date: January 21, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Patients with histologically diagnosed sarcomas that are associated with chromosomal translocation producing a fusion transcription factor oncogene.

• Patients must have measurable disease.

• A tissue block from primary or metastatic tumor must be available for confirmation of diagnosis, translocation subtype and correlative studies.

• Up to 1 prior chemotherapy regimen in the metastatic setting is permitted providing 28 days have elapsed.

• Prior radiation permitted provided a minimum of 28 days have elapsed.

• Surgery permitted provided at least 3 weeks have elapsed.

• Prior hormone therapy permitted.

• Patients must have life expectancy = 12 weeks.

• Metastatic or locally recurrent disease incurable with standard treatment.

• Acceptable end-organ function. ECOG 0, 1 or 2.

• granulocytes =1.5x10/9/L

• platelets =100x10/9/L

• bilirubin =UNL

• potassium =UNL

• calcium, magnesium within normal limits

• AST, ALT =2.5 x UNL

• serum creatinine =UNL or creatinine clearance =50mL/min

• QTc =450m sec

• LVEF =50%

• Troponin I or T = UNL

Exclusion Criteria:

• Cardiac exclusions; Patients with any preexisting uncontrolled cardiac condition.

• History of myocardial infarction at any time in the past.

• Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 5 years.

• Patients with documented CNS metastases, unless adequately treated with radiation at least 30 days prior to enrollment. Patients cannot have concurrent anti-convulsants or dexamethasone for control of symptoms. Patients with leptomeningeal disease, even with treatment, cannot be enrolled due to generally poor prognosis.

• Inability to take oral medication. Patients must be able to swallow SB939 capsules and have no gastrointestinal abnormalities (e.g. bowel obstruction or previous gastric resection) which would lead to inadequate absorption of SB939.

• Previous treatment with an HDAC inhibitor.

• Treatment with another investigational therapy or other anticancer therapy within 28 days prior to study entry.

• Known HIV, hepatitis B or hepatitis C infections.

• Dysrhythmic drugs - use of agents with a known risk of Torsades De Pointe is not permitted during the study. A comprehensive list can be found at http://torsades.org.

• Presence of any chronic medical condition or comorbidity such as pulmonary disease, active CNS disease, active infection, psychiatric condition, or laboratory abnormality that may increase the risks associated with study participation/study drug administration or may interfere with the interpretation of study results.

• Women or men who are not sterile unless they use an adequate method of birth control. Female patients that are post-menopausal for at least 12 months or are surgically sterile are considered sterile.

Related Conditions & MeSH terms

• Metastatic Sarcoma
• Sarcoma

Intervention

Drug:
• SB939
Given orally 3 times per week

Locations

Country	Name	City	State
Canada	Tom Baker Cancer Centre	Calgary	Alberta
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Ontario
Canada	London Regional Cancer Program	London	Ontario
Canada	McGill University - Dept. Oncology	Montreal	Quebec
Canada	Ottawa Health Research Institute - General Division	Ottawa	Ontario
Canada	Univ. Health Network-Princess Margaret Hospital	Toronto	Ontario
Canada	BCCA - Vancouver Cancer Centre	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
NCIC Clinical Trials Group	S*BIO

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associat — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the efficacy (as measured by objective response) of SB939 when given orally every other day 3 times a week, in patients with translocation-associated sarcomas.	The primary endpoint of this study is objective tumour response using RECIST 1.1 [Eisenhauer 2009]. Response is defined as 30% decrease in the sum of the diameters of the target lesions (partial response) maintained for at least 4 weeks, or complete disappearance of disease and cancer related symptoms (complete response), also maintained for at least 4 weeks. The median and range of the duration of response will be assessed. A 95% confidence interval for the true objective response rate will be given.	24 months
Secondary	Response duration, stable disease rate and progression free survival in these patients.		24 months
Secondary	Tolerability and toxicity of SB939, according to NCI CTCAE 4.0, in this population		24 months
Secondary	Potential molecular factors predictive of response in formalin fixed paraffin embedded specimens of patient sarcoma tissue		24 months